Results 101 to 110 of about 526 (116)

Afamelanotide for Prevention of Phototoxicity in Erythropoietic Protoporphyria

Expert Review of Clinical Pharmacology, 2021
Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity.
Janneke Langendonk, Debby Wensink, Margreet Wagenmakers   +2 more
exaly   +2 more sources

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine, 2015
BACKGROUND: Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life.
Robert J. Desnick, John Wilson, Herbert L Bonkovsky   +2 more
exaly   +4 more sources

Clinical and Dermoscopic Changes of Acquired Melanocytic Nevi of Patients Treated With Afamelanotide [PDF]

Photochemical and Photobiological Sciences, 2021
Background: Afamelanotide (AFA) is a synthetic analogue of α-melanocyte-stimulating hormone that is approved for the treatment of patients affected by erythropoietic protoporphyria (EPP).
Mariachiara Arisi, Mariateresa Rossi, C Tomasi   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Afamelanotide, an Agonistic Analog of α-Melanocyte-Stimulating Hormone, in Dermal Phototoxicity of Erythropoietic Protoporphyria

Expert Opinion on Investigational Drugs, 2010
Elisabeth I Minder
exaly  

Evaluation of the Immunogenicity of the Synthetic α-Melanocyte-Stimulating Hormone (α-MSH) Analogue Afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in Erythropoietic Protoporphyria Patients by ELISA Detecting Both Anti-Afamelanotide and Anti-α-MSH Antibodies

Skin Pharmacology and Physiology, 2015
Jasmin Barman-Aksözen, Elisabeth I Minder, Marcus Maurer   +2 more
exaly  

Afamelanotide (CUV1647) in Dermal Phototoxicity of Erythropoietic Protoporphyria

Expert Review of Clinical Pharmacology, 2015
Elisabeth I Minder
exaly  

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

JAMA Dermatology, 2020
John Wilson, Jasmin Barman-Aksözen, Janneke Langendonk   +2 more
exaly  

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

JAMA Dermatology, 2013
Henry W Lim, Iltefat H Hamzavi
exaly  

Afamelanotide: A Review in Erythropoietic Protoporphyria

American Journal of Clinical Dermatology, 2016
Karly P Garnock-Jones, Esther S Kim
exaly